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Abstract: The aim of this study was to assess the effects of DL-homocysteine (DL-Hcy) and DL-homocysteine thiolactone 
(DL-Hcy TLHC) on selected serum biochemical parameters, markers of oxidative stress and the activities of antioxidant 
enzymes (catalase (CAT), glutathione peroxidase (GPx), superoxide dismutase (SOD)) in the plasma, as well as on acetyl-
cholinesterase (AChE) activity in the cardiac tissue homogenate in the rat. Male Wistar rats were divided into three groups 
as follows: control group (1 mL 0.9% NaCl, intraperitoneal (i.p.) injection), DL-Hcy group (8 mmol/kg body mass (b.m.), 
i.p.) or DL-Hcy TLHC group (8 mmol/kg b.m., i.p.). One hour after administration, the rats were euthanized, whole blood 
was collected for biochemical analysis, and the heart was excised. Following the i.p. administration of DL-Hcy and DL-Hcy 
TLHC, the activities of antioxidant enzymes were mostly significantly increased, while plasma malondialdehyde (MDA) 
was decreased. Administration of DL-Hcy and DL-Hcy TLHC significantly inhibited AChE activity in rat cardiac tissue. 
Our findings suggest that DL-Hcy and DL-Hcy TLHC exerted prooxidant effects; however, the decrease in MDA points to 
an inverse response to the increase in antioxidant enzyme activities. While both substances inhibited AChE activity in rat 
cardiac tissue, DL-Hcy TLHC induced stronger effects than DL-Hcy.
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Abbreviations: ACh – acetylcholine; AChE – acetylcholinesterase; Alb – albumin; ALT – alanine aminotransferase; AMY 
– alfa amylase; AST – aspartate aminotransferase; CAT – catalase; CHD – coronary heart disease; Chol – cholesterol; CSE 
–  cystathionine gamma lyase; Crea – creatinine; DL-PAG – DL-propargylglycine; ECL – electrochemiluminescence immu-
noassay system; eNOS – endothelial nitric oxide synthase; Fibr – fibrinogen; Gluc – glucose; GPx – glutathione peroxidase; 
GSH – glutathione; Hcy – homocysteine; HHcy – hyperhomocysteinemia; HDL – high density cholesterol; HO-1 – heme 
oxygenase-1; hsTnT – high sensitivity troponin T; LDH – lactate dehydrogenase; LDL – low density cholesterol; L-NAME – 
Nω-nitro-L-arginine methyl ester; MDA – malondialdehyde; SOD – superoxide dismutase; TGL – triglycerides; TP – total 
protein; Urca – uric acid; VWF Act – Von Willebrand factor activity; ZnPPR IX – zinc protoporphyrin IX
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INTRODUCTION
Homocysteine (Hcy) is an endogenous sulfhydryl-
containing amino acid that is an intermediate product 
in the normal biosynthesis of the amino acids me-
thionine and cysteine [1]. Deficiency of the enzymes 
and/or vitamins that are involved in the homocysteine 
metabolic pathway leads to its increased levels in the 
plasma, referred to as hyperhomocysteinemia (HHcy) 
[2,3]. Data suggests that metabolic conversion of Hcy 
to the thioester Hcy-thiolactone contributes to Hcy 
pathobiology [4].
Literature findings indicate that there is a clear 
correlation between total serum Hcy and the inci-
dence of cardiovascular disease and its complications, 
such as heart attacks and strokes, thus promoting Hcy 
as a new and independent risk factor for these dis-
eases [5,6]. HHcy leads to endothelial dysfunction, 
which may further promote the proliferation of vas-
cular smooth muscle cells [7] and increase collagen 
synthesis in vascular smooth muscle cells [8]. There 
is evidence that HHcy is associated with increased 
ROS formation, including the superoxide anion radi-
cal (O2-) and hydrogen peroxide (H2O2) [9], thereby 
leading to oxidative stress and cell damage [10]. The 
main antioxidant enzymes responsible for controlling 
oxygen free radicals are SOD, CAT, and glutathione-
dependent enzymes, including GPx, GR and GST 
[10]. While it has been found that HHcy may impair 
the glutathione-related antioxidant defense system 
[11,12], data about its effect on SOD activity are still 
controversial.
While some studies showed that HHcy decreased 
erythrocyte SOD activity in patients with cardiovas-
cular disease (CVD) [12,13], others have established 
a positive relationship between SOD activity and Hcy 
levels in patients with homocystinuria [14]. Acetyl-
cholinesterase (AChE) is the serum protease that ter-
minates neurotransmission at cholinergic synapses by 
splitting the acetylcholine into choline and acetate, and 
it is predominantly distributed in different brain re-
gions [15]. Interestingly, elevated homocysteine levels 
increase AChE activity in the central nervous system 
[15,16], while homocysteine thiolactone slowly and 
irreversibly inhibits it [17]. Recent investigations have 
proved the presence of AChE activity in the heart [18].
Taking into account that the molecular mecha-
nisms of Hcy-induced cardiac effects are still poorly 
understood, this study aimed to examine the effect of 
DL-homocysteine and its thiolactone metabolite on 
serum biochemical parameters, markers of oxidative 
stress, the activities of antioxidant enzymes and car-
diac AChE activity in the rat.
MATERIALS AND METHODS
Chemicals
All chemicals were purchased from the Sigma Chemi-
cal Co. (USA).
Experimental animals
Male Wistar albino rats (n=36, 12 in each experimen-
tal group; 10 weeks old, body mass 250±30 g) were 
used. The rats were housed under strictly controlled 
conditions of air temperature (22±1°C), relative hu-
midity (50%) and a 12 h light/dark cycle (with the 
light period commencing at 9 am), with free access to 
water and standard food. All experimental procedures 
were performed in accordance with the EU Directive 
for the Protection of Vertebrate Animals used for Ex-
perimental and other Scientific Purposes 86/609/EES.
Experimental protocol
To produce acute HHcy, DL-homocysteine (DL-Hcy) 
and DL-homocysteine thiolactone (DL-Hcy TLHC) 
were administered i.p. in a single dose. Rats were di-
vided into three groups as follows: control group (1 
mL 0.9% NaCl, intraperitoneal (i.p.) injection), DL-
Hcy group (8 mmol/kg b.m., i.p.) or DL-Hcy TLHC 
group (8 mmol/kg b.m., i.p.). One hour after admin-
istration, the rats were euthanized, whole blood was 
collected for biochemical analysis, and the heart was 
excised. Saline and both Hcy compounds were ad-
ministered in the same volume (1 mL). Sixty min after 
application, the animals were killed using a rat guil-
lotine, blood samples were collected, and the heart 
was removed. After collection, the samples were kept 
at room temperature for 15 min, centrifuged for 15 
min at 2000 x g and analyzed.
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Serum biochemical parameters
The following serum biochemical parameters: Alb, 
ALT, AMY, AST, Chol, C, Fibr, Gluc, HDL, Hcy, hsT-
nT, LDH, LDL, TGL, TP, Urca, Urea, VWF Act, were 
analyzed using spectrophotometry and commercial 
kits (Siemens Healthcare Diagnostics Ltd. Frimley, 
Camberley, UK) on an automatic biochemical analyzer 
(Dimension Xpand, Siemens). An immunoturbidi-
metric commercial assay (Siemens Healthcare GmbH, 
Marburg, Germany) was used for the determination 
of fibrinogen and von Willebrand factor activity on 
a BCS XP coagulation analyzer (Siemens Healthcare 
GmbH, Marburg, Germany). Serum homocysteine was 
measured by an automated electrochemiluminescence 
immunoassay system ADVIA Centaur XP system (Sie-
mens Healthcare GmbH, Erlangen, Germany).
Determination of lipid peroxidation products
The MDA content in plasma was determined by the 
TBARS assay according to the standard procedure 
[19]. The values of MDA content (nmol of MDA/
mL plasma) were determined on the basis of absorb-
ance values and molar absorption coefficient of the 
malondialdehyde-thiobarbituric acid complex.
Determination of CAT activity
CAT activity was estimated by measuring the degrada-
tion of H2O2 [20]. The rate of decomposition of H2O2 
by CAT is measured spectrometrically at 230 nm. CAT 
activity was expressed as U/mL of plasma, with 1 U of 
enzyme activity defined as 1 μL of spent H2O2/min.
Determination of SOD
SOD activity was measured according to the method 
of Misra and Fridovich [21], with 1 U of SOD defined 
as the amount of enzyme that inhibits the rate of the 
epinephrine oxidation by 50%; enzyme activity was 
expressed as U/mL of plasma.
Determination of GPx activity
GPx activity was estimated essentially as described 
[22] and expressed as ΔA/min/mL of plasma.
Determination of AChE activity
AChE activity was determined in cardiac tissue ho-
mogenates. Heart tissue was homogenized (20 mg of 
tissue per 1 mL of phosphate buffer (pH 8.0, 0.1 M)) 
and centrifuged for 15 min at 10000 x g. The specific 
activity of AChE in the heart homogenate was deter-
mined in vitro by the method of Ellman [23].
Statistics
Statistical analysis of experimental data included the 
following basic descriptive statistics using the mean val-
ue (X)±standard error mean (SEM). Since the sample 
data do not have a normal distribution, in order to de-
termine statistically significant differences between the 
groups, the Kruskal-Wallis H test (the nonparametric 
alternative to the one-way ANOVA) was used, as well 
as multiple comparisons test and Pearson’s chi-square 
test. P<0.05 was considered to be significant. A database 
analysis of the results was performed using the software 
package SPSS 22th (SPSS Inc., Chicago, IL, USA).
RESULTS
Plasma biochemical parameters
The plasma values of biochemical parameters are ex-
pressed in standard units and are presented in Table 
1. It is important to note that the concentrations of 
Hcy in both experimental groups were >65 mmol/L. 
The glucose values were higher in DL-Hcy TLHC in 
comparison to both the control (p<0.05) and DL-Hcy 
groups (p<0.05). Total protein values were lower in the 
DL-Hcy group (p<0.01) when compared to the control 
and DL-Hcy TLHC groups (p<0.05). Alb, ALT and 
Fibr values were lower in both experimental groups 
as compared to the control (p<0.01), while the DL-
Hcy TLHC group had higher values of Alb than the 
DL-Hcy group (p<0.05). Chol and HDL values were 
higher in the DL-Hcy TLHC group in comparison 
to the control and DL-Hcy group (p<0.01, p<0.05). 
LDL values were higher in the DL TLHC group when 
compared to the control (p<0.01). Compared to the 
control group, serum AMY values were higher in both 
experimental groups (p<0.01) groups while the HDL 
values were higher in both DL-Hcy groups (p<0.05).
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Index of lipid peroxidation (MDA)
Administration of DL-Hcy (p<0.01) and DL-Hcy 
TLHC (p<0.05) induced a statistically significant 
decrease in MDA as compared to the control group 
(Fig. 1A).
CAT, GPx and SOD activities
Administration of DL-Hcy TLHC induced a statisti-
cally significant increase in CAT activity in the plasma 
as compared to the control group (p<0.01). Further-
more, there was significant increase of CAT activity 
after administration DL-Hcy TLHC when compared 
to the administration of DL-Hcy (p<0.05) (Fig. 1B).
The same trend in GPx activity was observed after 
the administration of DL-Hcy and DL-Hcy TLHC. 
Administration of DL-Hcy TLHC induced a statisti-
cally significant increase in GPx activity as compared 
to the control (p<0.01). There was highly significant 
increase in GPx activity after DL-Hcy TLHC adminis-
tration when compared to DL-Hcy (p<0.01) (Fig. 1C).
After DL-Hcy administration, SOD activity was 
statistically increased (p<0.01). DL-Hcy TLHC ad-
ministration decreased SOD activity without statistical 
significance. A highly significant increase in SOD ac-
tivity was noted after DL-Hcy administration in com-
parison to DL-Hcy TLHC administration (p<0.01) 
(Fig. 1D).
AChE activity
AChE activity was significantly decreased after the ad-
ministration of DL-Hcy (p<0.01) and DL-Hcy TLHC 
(p<0.01) as compared to the control (Fig. 2).
DISCUSSION
Our first objective was to investigate the influence of 
acute HHcy on different serum biochemical param-
eters in order to assess the systemic response to an 
DL-Hcy load. Our results showed that an acute rise in 
DL-Hcy and its thiolactone metabolite did not affect 
the concentrations of most routinely examined bio-
chemical markers (Table 1), the only exception being 
an increase in total cholesterol concentrations and its 
HDL and LDL fractions in rats treated with DL-Hcy 
TLHC. The data referring to the effect of increased 
Hcy on the lipid profile are debatable. A previous 
study of rats that received DL-Hcy TLHC for 30 days 
(1 g/kg body weight/day) showed elevated serum cho-
Table 1. Values of measured biochemical parameters in the plasma expressed in standard units (x±SEM).
Parameter/ Groups Control DL-Hcy DL-Hcy TLHC
(X±SE)
Gluc (mmol/L) 6.07±0.21 5.66±0.97 8.44±0.75 b*, c*
Urea (mmol/ L) 10.6±0.89 9.83±0.61 10.03±1.81
Crea (μmol/ L) 48.28±1.34 48.20±3.79 45.00±2.34
Urca (μmol/ L) 86.38±8.01 189.78±50.37 147.26±61.34
TP (g/L) 65.63±1.35 55.00±1.77a** 63.80±3.84 c*
Alb (g/L) 41.98±0.59 31.00±0.69 a** 35.20±1.96b**,c*
Chol (mmol/L) 1.39±0.65 1.61±0.10 2.03±0.19 b**,c*
HDL (mmol/L) 1.12±0.48 1.19±0.06 1.52±0.12b**,c*
LDL (mmol/L) 0.08±0.01 0.19±0.05 0.30±0.05b**
TGL (mmol/L) 0.59±0.05 0.52±0.08 0.46±0.09
AST (IU/L) 312.38±22.61 306.00±34.70 232.80±27.03
ALT (IU/L) 122.63±8.67 62.67±7.62a** 68.00±10.57b**
AMY (IU/L) 1281.50±83.50 2462.17±232.00a** 2398.20±304.51b**
hsTnT (ng/L) 25.80±6.20 40.88±7.14 19.75±7.36
LDH (IU/L) 3887.13±358.51 5655.00±605.73a* 3789.25±625.50 c*
Fibr (g/L) 2.60±0.26 1.06±0.04a** 1.07±0.07b**
VWF Act (%) 214.25±30.45 236.17±36.13 162.00±24.28
Statistical comparisons are marked as follows: a – control vs DL-Hcy p<0.05; b – control vs DL-Hcy TLHC; c – DL-Hcy vs DL-Hcy TLHC. P values less 
than 0.05 were considered to be significant (*p<0.05; **p<0.01).
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lesterol and triglycerides [24], with which our results 
agree. Interaction between Hcy and lipids is poorly 
understood, especially with regard to the activity of 
the enzyme paraoxonase. Nevertheless, it has been 
proposed that DL-Hcy induces endoplasmic reticulum 
stress and activates sterol regulatory element-binding 
proteins (SREBPs), which could increase the expres-
sion of genes responsible for cholesterol/triglyceride 
biosynthesis [25].
The kidneys are important in the 
removal of Hcy, and they could be 
affected by elevated plasma DL-Hcy 
levels. Although a recent investigation 
on mice suggests that persistently in-
creased levels of DL-Hcy induce extra-
cellular matrix remodeling and renal 
fibrosis [26], the parameters of renal 
function we examined (Urea, Crea and 
Urca) were not changed following the 
acute increase in DL-Hcy.
The liver possesses the highest 
catabolic capacity for DL-Hcy, and in-
creases in DL-Hcy or methionine levels 
can lead to liver oxidative/nitrosative 
stress [27]. Results linked with hepato-
cellular damage (AST and ALT) showed 
that HHcy is not linked to hepatocel-
lular damage; however, the observed 
lower levels of serum Alb and Fibr in 
both experimental groups indicate that 
there is an initial impairment of liver 
function. Disturbed fibrinogen levels may occur due 
to an established process of homocysteine vs proteins 
interactions. Recent studies have demonstrated that 
treatment with methionine for 8 weeks (100 mg/kg) 
led to liver dysfunction through increased ROS pro-
duction [28].
The observed alterations in serum glucose and 
AMY concentrations in acute HHcy could be linked 
with pancreatic dysfunction. Also, the higher glucose 
concentration in the DL-Hcy TLHC group could be 
the result of insulin resistance. A previous study on 
rats has shown that HHcy was associated with a de-
crease in the glucose:insulin ratio and an increase in 
the insulin resistance index [29]. It was also found 
that a 2-week treatment with DL-Hcy decreased the 
cerebral expression of GLUT-1 and produced a con-
comitant increase in the percentage of damaged cer-
ebral vessels in rats [30].
In addition, we observed increased levels of hsTnT 
(very close to statistical significance) and LDH, as 
indicators of cardiac and brain damage. The limited 
metabolic capacity for DL-Hcy in the cardiovascular 
system might be linked to injury of the cardiovascular 
system induced by Hcy.
Fig. 2. The effects of DL-Hcy and DL-Hcy TLHC on AChE activ-
ity in rat heart. P<0.05 was considered to be significant (*p<0.05; 
**p<0.01).
Fig. 1. The effects of DL-Hcy and DL-Hcy TLHC on selected markers of oxidative 
stress in rat plasma. A – MDA concentration; B – CAT activity; C – GPx activity; 
D – SOD activity. P values less than 0.05 were considered to be significant (*p<0.05; 
**p<0.01).
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Our study showed that both DL-Hcy and DL-Hcy 
TLHC decreased MDA, while there was no significant 
difference between these experimental groups and its 
metabolite. These results are not in agreement with 
the results of other studies where it was shown that 
acute HHcy increased lipid peroxidation in rats [11]. 
Additionally, it was shown [9] that chronic DL-Hcy ad-
ministration also promoted oxidative damage by lipid 
peroxidation [31]. However, we did not note changes in 
the index of lipid peroxidation in the isolated rat heart 
treated with three isoforms of 10 μM homocysteine 
(DL-Hcy, DL-Hcy TLHC and L-Hcy TLHC) [32]. The 
discrepancy between our results and the mentioned 
investigations may be due to the acute application of 
substances and the resulting lack of time for achieving 
their negative effects on oxidative stress markers.
Having in mind that GPx-1 may be a key target of 
the deleterious actions of DL-Hcy [33], it was important 
to attempt to reveal the complex relationship between 
HHcy and the activity of this enzyme. We showed that 
the basic form of DL-Hcy did not significantly affect 
GPx activity, while DL-Hcy TLHC induced an increase 
in the activity of this enzyme. One possible explanation 
for the rise in GPx activity could be the chemical reac-
tivity of the toxic thiolactone metabolite, which pos-
sesses the ability to cause prominent activation of the 
glutathione antioxidant system [34]. In contrast, other 
investigations found that in acute HHcy, GPx activ-
ity was decreased in a similar experimental model (0.6 
μmol DL-Hcy/g body weight) [11]. Nevertheless, the 
authors used a much lower concentration of DL-Hcy, 
which may be not have been enough to mobilize this 
part of the defense system.
On the other hand, we observed completely op-
posite results in the case of SOD activity. Namely, the 
application of DL-Hcy led to a significant increase in 
SOD, while DL-Hcy-TLHC did not change it. Litera-
ture data referring to the DL-Hcy-SOD relation are 
controversial. Previous studies in rats have shown that 
3 weeks of DL-Hcy administration decreased SOD 
levels in the plasma [9,31]. However, although the 
time under HHcy was prolonged, its concentration 
was more than 1000 times lower, which may be the 
reason for the difference to our investigation. In ad-
dition, other investigations found that patients with 
significantly elevated DL-Hcy have elevated SOD 
levels [14]. Based on the abovementioned, it would 
seem that concentration determines the direction of 
DL-Hcy toward SOD, i.e. in mild HHcy, SOD is de-
creased while in prominent HHcy the activity of this 
enzyme is strongly activated.
Unlike SOD, CAT values showed a different dy-
namic. Thus, only the thiolactone form induced a sig-
nificant increase in plasma CAT activity. Recent investi-
gations on animal models also observed increased CAT 
activity 15 min after acute DL-Hcy administration, 
suggesting that the oxidative status of rats was altered 
[11]. Taking into consideration the increased activities 
of all antioxidant enzymes, we suggested that DL-Hcy 
and DL-Hcy TLHC have prooxidant effects. However, 
the decrease in MDA levels during the same period 
could mean that the rise in antioxidant activity was 
inversed. In contrast, chronic administration of DL-
Hcy can decrease CAT levels in the plasma, heart and 
aorta, which are accompanied by histological changes 
[9]. This finding indicates that, besides changed con-
centrations, the duration of HHcy can also contribute to 
the effects of DL-Hcy on antioxidative enzyme activity. 
The potential mechanisms of DL-Hcy-induced changes 
in antioxidant defense enzymes probably include dif-
ferent interactions of ROS and DL-Hcy [9].
As previously described [17], it has been assumed 
that the harmful effects of elevated homocysteine could 
in part be due to its actions on cholinesterases. In the 
available literature, there is almost no information 
concerning the effects of DL-Hcy on AChE activity 
in the heart. According to the presented results, both 
DL-Hcy and DL-Hcy TLHC decreased AChE activity 
in cardiac tissue homogenates (Fig. 2). However, the 
thiolactone form induced a more prominent decrease in 
AChE activity, revealing its more deleterious influence 
on cardiac tissue than Hcy itself. Investigations on hu-
man subjects also found that thiolactone slowly and ir-
reversibly inhibited the activity of AChE in plasma [17]. 
Interestingly, in a recent paper [18] it was suggested 
that increased cholinergic tone in the heart caused by 
cholinesterase inhibitors has a positive effect on some 
cardiovascular disorders such as heart failure.
CONCLUSION
The results of the present study suggest that acute 
application of different forms of DL-Hcy can elicit 
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responses in different organs. Following acute i.p. 
administration of DL-Hcy or DL-Hcy TLHC, the 
activities of antioxidant enzymes in the plasma were 
significantly increased. Our findings demonstrate that 
these amino acids have prooxidant effects. In addition, 
the obtained results were dependent on the form of 
acutely applied DL-Hcy.
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